Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. Malapelle U, et al. Among authors: verze m. Eur J Cancer. 2021 Mar;146:74-83. doi: 10.1016/j.ejca.2021.01.015. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588147 Review.
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Leonetti A, Minari R, Boni L, Gnetti L, Verzè M, Ventura L, Musini L, Tognetto M, Tiseo M. Leonetti A, et al. Among authors: verze m. Clin Lung Cancer. 2021 Sep;22(5):473-477. doi: 10.1016/j.cllc.2021.02.014. Epub 2021 Feb 24. Clin Lung Cancer. 2021. PMID: 33762169 Clinical Trial.
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review.
Leonetti A, Minari R, Mazzaschi G, Gnetti L, La Monica S, Alfieri R, Campanini N, Verzè M, Olivani A, Ventura L, Tiseo M. Leonetti A, et al. Among authors: verze m. Front Oncol. 2021 Apr 26;11:642190. doi: 10.3389/fonc.2021.642190. eCollection 2021. Front Oncol. 2021. PMID: 33981604 Free PMC article.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Verzè M, Minari R, Gnetti L, Bordi P, Leonetti A, Cosenza A, Ferri L, Majori M, De Filippo M, Buti S, Gasparro D, Nizzoli R, Azzoni C, Bottarelli L, Squadrilli A, Mozzoni P, Tiseo M. Verzè M, et al. Cancers (Basel). 2021 Oct 28;13(21):5403. doi: 10.3390/cancers13215403. Cancers (Basel). 2021. PMID: 34771566 Free PMC article.
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
Perrone F, Mazzaschi G, Minari R, Verzè M, Azzoni C, Bottarelli L, Nizzoli R, Pluchino M, Altimari A, Gruppioni E, Sperandi F, Andrini E, Guaitoli G, Bertolini F, Barbieri F, Bettelli S, Longo L, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, Gnetti L, Tiseo M. Perrone F, et al. Among authors: verze m. Cancers (Basel). 2022 Apr 16;14(8):2019. doi: 10.3390/cancers14082019. Cancers (Basel). 2022. PMID: 35454926 Free PMC article.
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
Mazzaschi G, Perrone F, Minari R, Verzè M, Azzoni C, Bottarelli L, Pluchino M, Armillotta MP, Ubaldi A, Altimari A, Gruppioni E, Sperandi F, Andrini E, Guaitoli G, Bettelli S, Longo L, Bertolini F, Barbieri F, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, Gnetti L, Tiseo M; DETECTION study group. Mazzaschi G, et al. Among authors: verze m. Clin Lung Cancer. 2022 Nov;23(7):e478-e488. doi: 10.1016/j.cllc.2022.07.005. Epub 2022 Jul 25. Clin Lung Cancer. 2022. PMID: 36002369
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
Perrone F, Favari E, Maglietta G, Verzè M, Pluchino M, Minari R, Sabato R, Mazzaschi G, Ronca A, Rossi A, Cortellini A, Pecci F, Cantini L, Bersanelli M, Quaini F, Tiseo M, Buti S. Perrone F, et al. Among authors: verze m. Cancer Immunol Immunother. 2023 Jul;72(7):2127-2135. doi: 10.1007/s00262-023-03398-3. Epub 2023 Feb 24. Cancer Immunol Immunother. 2023. PMID: 36828963 Free PMC article.
23 results